Philip Grossen

TL;DR: This review discusses state‐of‐the‐art nanomedicines based on PEG‐PCL that have been investigated in a preclinical setting and highlights recent therapeutic applications investigated in vitro and in vivo using advanced systems such as triggered release, multi‐component therapies, theranostics, or gene delivery systems.

TL;DR: A review of lipid-based DNA delivery systems can be found in this article, where the authors discuss state-of-the-art lipid based DNA delivery system that have been investigated in a preclinical setting.

TL;DR: Several advantageous features of the zebrafish model, such as biological conservation, imaging modalities, availability of genetic tools and disease models, as well as their various applications in nanomedicine development, are outlined.

TL;DR: The findings indicate that the zebrafish model is a useful vertebrate screening tool for nanoparticulate drug delivery systems to predict their in vivo circulation behavior with respect to systemic circulation time and exposure.

TL;DR: Zebrafish embryos are validated as an emerging vertebrate screening tool to assess the macrophage sequestration of surface modified particulate formulations with varying particle size under realistic biological conditions and a strategy for efficient, systematic and rapid nanomedicine optimization is presented in order to facilitate the preclinical development of nanotherapeutics.